2nd Quarter - Report

CARIS LIFE SCIENCES, INC. for CARIS LIFE SCIENCES, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$79,611
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2011 $79,611 Replaced
2nd Quarter - Report Oct 20, 2011 $56,867 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.

LobbyistCovered position, as disclosed
AMY JENSEN CUNNIFFE Asst. to the Speaker of the House for Policy

Contacted: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.

LobbyistCovered position, as disclosed
AMY JENSEN CUNNIFFE Asst. to the Speaker of the House for Policy

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP)

Medical/Disease Research/Clinical Labs MED

Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organization, Sustainable Growth Rate reform, pathology reimbursement issues.

LobbyistCovered position, as disclosed
AMY JENSEN CUNNIFFE Asst. to Speaker of the House for Policy

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS)

Insurance INS

Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.

LobbyistCovered position, as disclosed
AMY JENSEN CUNNIFFE Asst. to the Speaker of the House for Policy

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.